Higher levels of antibodies to the tumour-associated antigen cyclin B1 in cancer-free individuals than in patients with breast cancer

Clinical and Experimental Immunology

Volumn 178, Issue 1, 2014, Pages 75-78

  Pandey, J P ^a   Kistner Griffin, E ^a   Namboodiri, A M ^a   Iwasaki, M ^b   Kasuga, Y ^c   Hamada, G S ^d   Tsugane, S ^e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Division of Epidemiology Nagano Matsushiro General Hospital   (United States)

^c Nagano Matsushiro General Hospital   (Japan)

^d Nikkei Disease Prevention Center   (Brazil)

^e NATIONAL CANCER CENTER   (Japan)

Author keywords

Antibodies; Breast cancer; Cyclin B1; Immunosurveillance; Tumourassociated antigen

Indexed keywords

COMPLEMENT COMPONENT C1Q; CYCLIN B1; IMMUNOGLOBULIN G ANTIBODY; MUCIN 1; ANTIBODY; CCNB1 PROTEIN, HUMAN; IMMUNOGLOBULIN G; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EFFECTOR CELL; ETHNICITY; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; PHAGOCYTOSIS; TUMOR CELL; BREAST TUMOR; FEMALE; IMMUNOLOGY;

ANTIBODIES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CYCLIN B1; FEMALE; HUMANS; IMMUNOGLOBULIN G;

EID: 84908167906     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12385     Document Type: Article

References (15)

1. Kao H, Marto JA, Hoffmann TK et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001; 194:1313-23.
2. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006; 66:6-9.
3. Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci USA 2009; 106:14010-5.
4. Vella LA, Yu M, Phillips AB, Finn OJ. Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice. Ann NY Acad Sci 2009; 1174:68-73.
5. Iwasaki M, Shimada N, Kasuga Y et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res Treat 2011; 126:497-505.
6. Egloff AM, Weissfeld J, Land SR, Finn OJ. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann NY Acad Sci 2005; 1062:29-40.
7. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005; 11:1521-6.
8. Andersen RS, Sørensen RB, Ritter C et al. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol Immunother 2011; 60:227-34.
9. Lu H, Ladd J, Feng Z, Wu M et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) 2012; 5:1036-43.
10. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18:574-83.
11. Pinheiro SP, Hankinson SE, Tworoger SS et al. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010; 19:1595-601.
12. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003; 103:97-100.
13. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161:589-94.
14. Klein G. Evolutionary aspects of cancer resistance. Semin Cancer Biol 2014; 25:10-4.
15. McCarthy N. A growing concern. Nat Rev Cancer 2014; 14:154.